Intra-individual variation and sex differences in gene expression of cytochromes P450 in circulating leukocytes

被引：36

作者：

Finnström N. ^{[1
]}

Ask B. ^{[1
]}

Dahl M.-L. ^{[1
]}

Gadd M. ^{[1
]}

Rane A. ^{[1
]}

机构：

[1] Dept. of Med. Lab. Sciences/Technol., Division of Clinical Pharmacology, Huddinge University Hospital

来源：

The Pharmacogenomics Journal | 2002年 / 2卷 / 2期

关键词：

Cytochrome P450; Intra-individual variation; Leukocyte; Real-time PCR;

D O I：

10.1038/sj.tpj.6500086

中图分类号：

学科分类号：

摘要：

To clarify partly inconsistent results in gene expression of cytochromes P450 (CYP) in the circulation, we undertook a systematic study over a long time period in 19 healthy men and women. CYP specific mRNA for 1A2, 1B1, 2E1 and 3A4 was studied in the leukocytes collected repeatedly on 20 occasions over a 10-week period. Our study revealed a varying pattern of CYP expression over time. CYP3A4 specific mRNA exhibited the largest intra-individual variation with an average coefficient of variation between 40 and 250%. CYP1B1 and CYP2E1 did not vary as much (39-110%). CYP1A2 was sporadically detected in only ten individuals, but varied considerably when measurable (61-256%). The expression in CYP1B1 was significantly higher in women than in men (P = 0.02). We conclude that CYP gene expression in blood varies considerably over time. It is conceivable that the variation reflects a hitherto unknown influence of exogenous or endogenous factors such as hormones, cytokines, and other circulating factors on the hematogeneous cytochromes.

引用

页码：111 / 116

页数：5

共 29 条

[1]

Meyer U.A., Overview of enzymes of drug metabolism, J. Pharmacokin. Biophormaceut, 24, pp. 449-459, (1996)

[2]

de Wildt S.N., Kearns G.L., Leeder J.S., van den Anker J.N., Cytochrome P450 3A: Ontogeny and drug disposition, Clin. Pharmacokinet, 37, pp. 485-505, (1999)

[3]

Kivisto K.T., Griese E.-U., Fritz P., Linder A., Hakkola J., Raunio H., Et al., Expression of cytochrome P450 3A enzymes in human lung: A combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours, Naunyn-Schmiedeberg's Arch. Pharmacol, 353, pp. 207-212, (1996)

[4]

Raucy J.L., Ingelman-Sundberg M., Carpenter S., Rannug A., Rane A., Franklin M., Et al., Drug metabolizing enzymes in lymphocytes, J. Biochem. Mol. Toxicol, 13, pp. 223-226, (1999)

[5]

Ingelman-Sundberg M., Oscarson M., McLellan R.A., Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment, Trends Pharmacol. Sci, 20, pp. 342-349, (1999)

[6]

Why bother about cytochrome P450 enzymes?, Drug Ther. Bull, 38, pp. 93-95, (2000)

[7]

Andersen M.R., Farin F.M., Omiecinski C.J., Quantification of multiple human cytochrome P450 mRNA molecules using competitive reverse transcriptase-PCR, DNA Cell Biol, 17, pp. 231-238, (1998)

[8]

Finnstrom N., Bjelfman C., Thorn M., Loof L., Rane A., Quantitation of cytochrome P450 mRNAs in patients with suspected liver diseases as assessed by reverse transcriptase-PCR, J. Lab. Clin. Med, 134, pp. 133-140, (1999)

[9]

Finnstrom N., Thorn M., Loof L., Rane A., Independent patterns of cytochrome P450 gene expression in human blood and liver, Eur. J. Clin. Pharm, 57, pp. 403-409, (2001)

[10]

Kellermann G., Luyten-Kellermann M., Shaw C., Metabolism of polycyclic aromatic hydrocarbons in cultured human leukocytes under genetic control, Humangenetik, 20, pp. 257-263, (1973)

← 1 2 3 →